WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Benefits of statin therapy may extend beyond lowering lipids

Details
Research
04 January 2012
People with high cholesterol are at risk of heart attack and stroke because atherosclerotic plaques within their arteries can rupture triggering the formation of a blood clot called an occlusive thrombus that cuts off the blood supply to their heart or brain.
Read more ...

Missing trial data threatens the integrity of medicine

Details
Research
03 January 2012
Missing clinical trial data can harm patients and lead to futile costs to health systems, warn experts as part of an in-depth BMJ review of the matter. Missing data is a serious problem in clinical research. It distorts the scientific record, so that clinical decisions cannot be based on the best evidence.
Read more ...

Hepatitis C virus hijacks liver microRNA

Details
Research
02 January 2012
Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment.
Read more ...

Ovarian cancer study proves drug delays disease progression

Details
Research
28 December 2011
Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.
Read more ...

Scientists Fixate on Ric-8 to Understand Trafficking of Popular Drug Receptor Targets

Details
Research
27 December 2011
Half the drugs used today target a single class of proteins - and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.
Read more ...

Viagra against heart failure

Details
Research
26 December 2011
How sildenafil, the active ingredient in Viagra, can alleviate heart problems is reported by Bochum's researchers in cooperation with colleagues from the Mayo Clinic in Rochester (Minnesota) in the journal Circulation.
Read more ...

NIH scientists find a potential new avenue for cancer therapies

Details
Research
20 December 2011
Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.
Read more ...

More Pharma News ...

  1. A gene that protects against colorectal cancers
  2. New light on medicinal benefits of plants
  3. Blood test might predict how well a depressed patient responds to antidepressants
  4. Commercial or communal: Why is outsourcing taboo for churches and pharmaceutical companies?
  5. Scientists discover new way to target cancer
  6. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
  7. Plasma-based treatment goes viral
  • Start
  • Prev
  • 268
  • 269
  • 270
  • 271
  • 272
  • 273
  • 274
  • 275
  • 276
  • 277
  • Next
  • End
Tahmeena

Business & Industry

  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed
  • Bayer to accelerate drug discovery with Google Cloud's high-performance compute power
  • NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Research & Development

  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic
  • Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations
  • Study identifies potential new approach for treating lupus

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.